Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Casgevy“
Suchtreffer
Begriffe & Kennungen
Casgevy
Eintrag öffnenCasgevy · 4.1 Therapeutic indications · 1
Eintrag öffnenCasgevy · 4.3 Contraindications · 1
Eintrag öffnenCasgevy · 4.3 · Contraindications to mobilisation and myeloablative conditioning medicinal products must be considered.
Eintrag öffnenCasgevy · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCasgevy · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenCasgevy · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenCasgevy · 4.5 · Discontinue the use of voxelotor and crizanlizumab at least 8 weeks prior to start of mobilisation and conditi
Eintrag öffnenCasgevy · 4.5 · Iron chelators must be discontinued at least 7 days prior to initiation of myeloablative conditioning, due to
Eintrag öffnenCasgevy · 4.5 · Live vaccines
Eintrag öffnenCasgevy · 4.5 · No formal drug interaction studies have been performed. Casgevy is not expected to interact with the hepatic c
Eintrag öffnenCasgevy · 4.5 · The drug-drug interaction of mobilisation and myeloablative conditioning medicinal products must be considered
Eintrag öffnenCasgevy · 4.5 · The safety of immunisation with live viral vaccines during or following Casgevy treatment has not been studied
Eintrag öffnenCasgevy · 4.5 · Use of hydroxyurea/hydroxycarbamide must be discontinued at least 8 weeks prior to start of mobilisation and c
Eintrag öffnenCasgevy · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenCasgevy · 4.8 Undesirable effects · 1
Eintrag öffnenCasgevy · 4.8 · 10 General disorders and Pain, pyrexia administration site conditions * Musculoskeletal pain included back pai
Eintrag öffnenCasgevy · 4.8 · 12 Description of selected adverse reactions
Eintrag öffnenCasgevy · 4.8 · 13 professionals are asked to report any suspected adverse reactions via the national reporting system listed
Eintrag öffnenCasgevy · 4.8 · A life-threatening serious adverse reaction of cerebellar haemorrhage occurred in 1 (1.9%) patient with TDT an
Eintrag öffnen